On Dec. 22, the U.S. Food and Drug Administration (FDA) approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH). Read more.
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.